Industry leader Francisco De La Vega joins Ultima to accelerate advancements in germline genome sequencing. 0 2 minutes read FREMONT, Calif., May 18, 2026 /PRNewswire/ - Ultima Genomics today announced Francisco De La Vega, DSc, has joined the Company as Vice President, Germline Genomics & Distinguished Scientific Fellow. With over 25 years of leadership experience in human genetics, computational biology, and bioinformatics, Francisco will drive Ultima's inherited genome analysis applications to unlock insights into genetic diseases, population health, and personalized medicine. Francisco has held senior leadership positions at leading companies including Applied Biosystems, where he was named a Distinguished Fellow, and at innovative startups such as Fabric Genomics (Chief Scientific Officer), Tempus AI (VP of Hereditary Disease), and Galatea Bio (Chief Technology Officer). His contributions have propelled advances in genetic analysis technologies, bioinformatics tools, AI-enabled genome interpretation, and clinical genetic testing, earning him multiple awards. Notably, Francisco also played leading roles in the landmark 1000 Genomes Project and the International Cancer Genome Consortium. "Ultima has made tremendous progress in reducing the cost of sequencing and solving unique accuracy needs, particularly in oncology and liquid biopsy," said Dr. De La Vega. "With the Company's second-generation UG200 instrument, the improvements of the Solaris 2.0 chemistry, and exceptional scalability roadmap, I saw a compelling opportunity to help Ultima advance germline genome sequencing. As newborn screening, biobank sequencing, and national genomics initiatives continue to expand, technology that can deliver a combination of low cost, high accuracy and high throughput is essential to making genomic medicine accessible to all who can benefit." Beyond his industry achievements, Francisco is an Adjunct Professor at Stanford University, has served on the ISCB Board of Directors, and is the co-author of over 100 scientific publications with nearly 50,000 citations. He received his Doctorate of Science from CINVESTAV, Mexico. "We are thrilled to welcome Francisco to Ultima Genomics," said Gilad Almogy, Founder and CEO. "His deep expertise in germline genomics and proven leadership in advancing genetic analysis technologies will be invaluable as we push the boundaries of genome sequencing. Francisco's vision aligns perfectly with our mission to make high-quality genomic information accessible and affordable, accelerating discoveries that can improve human health." Francisco's appointment marks a pivotal step in Ultima's strategy to drive innovation in germline genomics. His extensive background in developing advanced genetic analysis solutions will help Ultima expand applications of its sequencing technology, supporting new research, clinical initiatives, and collaborations. His addition also underscores Ultima's commitment to making advanced genomic science accessible and impactful for researchers and clinicians worldwide. About Ultima Genomics Ultima Genomics is unleashing the power of genomics at scale. The Company's mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology's complexity and dynamic change - and a further need to challenge conventional next-generation sequencing technologies. Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century. To learn more, visit www.ultimagenomics.com. SOURCE Ultima Genomics

Ultima Genomics has appointed Francisco De La Vega as Vice President, Germline Genomics & Distinguished Scientific Fellow. De La Vega brings over 25 years of experience in human genetics, computational biology and bioinformatics. De La Vega previously held senior positions at Applied Biosystems, Fabric Genomics, Tempus AI and Galatea Bio. He played leading roles in the 1000 Genomes Project and International Cancer Genome Consortium, and has co-authored over 100 scientific publications with nearly 50,000 citations. At Ultima, De La Vega will drive inherited genome analysis applications across genetic diseases, population health and personalised medicine. His appointment supports Ultima's expansion into germline genomics, particularly as newborn screening, biobank sequencing and national genomics initiatives grow globally.

Basecamp Research launches Trillion Gene Atlas to scale ai-designed therapeutics. Mar 18, 2026, 05:00 ET * The Atlas will expand known evolutionary genetic diversity by 100x, collecting novel genomic data from over 100 million new species across thousands of sites globally. * By partnering with Anthropic, Ultima Genomics, and PacBio, and powered by NVIDIA AI infrastructure, Basecamp Research aims to compress over two decades of biological data gathering and analysis into less than two years. * Training the EDEN models revealed new scaling laws: as biological datasets grow larger and richer, AI capabilities jump - opening the door to systems that can design new medicines across diseases and treatment types. AUSTIN, Texas and SAN JOSE, Calif., March 18, 2026 /PRNewswire/ - Basecamp Research, a frontier AI lab for biological design, today announced the launch of the Trillion Gene Atlas, a landmark scientific initiative to generate and model biological data at the trillion-gene scale. Launched in collaboration with Anthropic, Ultima Genomics and PacBio, and powered by NVIDIA AI infrastructure, the Trillion Gene Atlas aims to expand known evolutionary genetic diversity 100-fold by collecting genomic data from more than 100 million species across thousands of sites worldwide. This is possible thanks to Basecamp Research's growing network of global biodiversity partners. Its ultimate goal is to provide the vast, diverse training data required for AI systems to learn from evolution to design new medicines on demand. "Today's biological AI models are trained on a narrow slice of life on Earth," said Glen Gowers, Co-founder and CEO of Basecamp Research, speaking at SXSW in Austin. "The Trillion Gene Atlas expands the known genetic universe by orders of magnitude beyond what is in public databases. Training models at this scale establishes a new paradigm for programmable therapeutic design." The initiative, which is on the scale of the Human Genome Project, was unveiled during the Health Track at SXSW and the NVIDIA GTC conference in San Jose. Addressing the Biological Data Bottleneck With huge increases in model size and computing power, diverse data is a critical enabler for progress in AI drug development and real-world benchmarks. All current sequence-based foundation models rely on variants of the same public repositories, with 80% of these trained on a public database containing fewer than 250 million sequences. Basecamp Research's EDEN foundation models, released in January, bypass the industry's evolutionary "data wall" by training entirely on BaseData(TM), a proprietary genomic database that is currently more than 10 times larger than all public resources combined. By learning from an unprecedented 10 billion new-to-science genes across 1 million newly discovered species, EDEN unlocked critical new scaling laws for AI in biology. This massive expansion in dataset diversity moved EDEN beyond simple prediction, making it the first model capable of designing diverse therapeutics directly from a disease prompt. In wet-lab validation, EDEN demonstrated zero-shot activity in primary human T-cells without any human or clinical data needed. The model has successfully generated hits across multiple frontier modalities, notably pioneering AI-Programmable Gene Insertion (aiPGI) to insert healthy genes and designing targeted antimicrobial peptides with a 97% hit rate against priority pathogens. The Trillion Gene Atlas builds on this approach by greatly expanding the breadth and contextual depth of genomic data in the known "internet of biology" suitable for AI training. "Bigger models alone aren't enough," added Phil Lorenz, CTO of Basecamp Research. "EDEN showed that performance in biological AI follows much steeper scaling trajectories with higher quality and fully contextualized data. The Trillion Gene Atlas extends that principle 100-fold." Global Biodiversity Partnerships Over the past six years, Basecamp Research has built a network of scientific collaborators across 31 countries, establishing a scalable evolutionary genomics pipeline purpose-built for AI training. By pioneering a combination of new regulatory and economic frameworks and fully off-grid DNA sequencing technologies, the company collects high-quality genomic data from ecosystems beyond the reach of traditional laboratories. These partnerships are grounded in knowledge exchange, local capacity building, and equitable Access and Benefit-Sharing agreements aligned with emerging Digital Sequence Information regulations. This framework enables responsible, large-scale, high-quality genomic data collection while investing in scientific infrastructure and training within partner regions. As part of the Atlas launch, Basecamp is announcing new partnerships in Chile, Argentina and an expanded collaboration in Antarctica, further extending its global biodiversity network. Scaling Data Generation and Compute with Ultima Genomics, PacBio and NVIDIA The Trillion Gene Atlas is enabled by advances in ultra-high-throughput short- and long-read sequencing and accelerated computing. Basecamp has partnered with Ultima Genomics and PacBio to deliver industrial-scale sequencing including data-rich, high-accuracy long reads. Ultima is a developer of ultra-high throughput next- generation sequencing (NGS) systems. Ultima's latest sequencing system, the UG200 Series, advances the company's unique wafer-based sequencing architecture to enable high-throughput, whole-genome and multi-omics sequencing at an industrial scale at a low price point to enable initiatives like the Trillion Atlas. "Biology has been fundamentally data-starved when compared to other fields like language or computer vision as researchers have lacked the tools required to generate data at scale" said Gilad Almogy, Founder and CEO of Ultima Genomics. "We strongly believe that AI will have an immense impact on our understanding of biology and human health, and the UG200 Series was designed from the ground up to enable the massive datasets required for BioAI to deliver on this promise. We are excited our technology can enable Basecamp in their vision and advance innovative initiatives like the Trillion Gene Atlas." "PacBio HiFi sequencing delivers highly accurate long reads that preserve full genomic context and enables subspecies and even strain-level resolution in complex samples." said Christian Henry, President and CEO of PacBio. "HiFi data provides the reliable, information-rich foundation biological AI models need to learn from nature at scale and power initiatives like the Trillion Gene Atlas." The Trillion Gene Atlas will be powered by NVIDIA's accelerated computing infrastructure to process vast quantities of genetic data at the petabase scale. As part of this effort, Basecamp plans to leverage NVIDIA Parabricks to significantly accelerate metagenomic assembly. This collaboration focuses on both advanced engineering and the development of new algorithmic methods to optimize how complex environmental samples are reconstructed. Thanks to this acceleration, processing quadrillions of DNA base pairs, a task that would have previously taken over 20 years, is expected to take less than two years to complete. Through parallelized data processing, automated annotation, and large-scale model training, the partners expect to compress a task that previously would have required more than 20 years of processing time to less than two years. This compression of sequencing, assembly, annotation and model training is intended to expand the performance and scope of biological foundation models across therapeutic development. Creating an Agentic End-to-End Therapeutic Design Workflow Anthropic joins as part of its broader effort to add new capabilities for life sciences: connecting Claude to more scientific platforms. Working with the Claude for Life Sciences team, the aim is to harness the Trillion Gene Atlas and EDEN to make Claude an even more productive research partner for scientists and clinicians, and support organisations bringing new scientific advancements to the public. By combining Claude's advanced reasoning capabilities, EDEN's therapeutic design capabilities, and NVIDIA's CUDA-X Libraries to process unstructured data, the initiative aims to create an integrated workflow for interpreting complex clinical data and translating it directly into therapeutic design. The Trillion Gene Atlas is built on three pillars: large-scale DNA sequencing, global data supply partnerships and advanced computing. Together with AI systems capable of reasoning across complex data, these foundations can help turn vast datasets into therapeutic discoveries. By increasing the evolutionary data available to AI by another 100x, Basecamp Research aims to make drug design faster and more systematic - extending EDEN's earlier advances in fields like gene therapy and the fight against antibiotic-resistant bacteria.